Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Sepracor-Looks very promising -- Ignore unavailable to you. Want to Upgrade?

To: Don Miller who wrote (3819)	10/26/1999 1:41:00 PM
From: Biomaven	Read Replies (2) \| Respond to of 10280

Here we go: MADISON, N.J., Oct 20 (Reuters) - Drug company Schering-Plough Corp. (NYSE:SGP) reported a 21 percent gain in third quarter earnings per share, driven by strong pharmaceutical sales growth worldwide. Schering-Plough earned $518 million, or 35 cents a share, in line with analysts's expectations, compared to $432 million, or 29 cents a share, in the year-ago third quarter. Third quarter sales of $2.24 billion were 13 percent higher than the $2.0 billion last year. Foreign exchange had no impact on the sales increase. The company said it expects to approach a 20 percent gain in full-year 1999 earnings per share over 1998. Higher worldwide pharmaceutical sales were led by the Claritin line of nonsedating antihistamines and the antiviral/anticancer agent Intron A. All the drug stocks have been weak recently, probably because of political worries about drug/Medicare pricing. Peter